"With early detection as the leading defense against breast cancer it is crucial that radiologists are armed with the right technology to inform diagnoses," said Rob Fabrizio, Director of Strategic Marketing, Digital Radiography and Women's Health, FUJIFILM Medical Systems U.S.A., Inc. "The ASPIRE Bellus II, a one-stop workstation solution designed specifically for mammographic diagnosis, aims to streamline workflow and optimize image displays enabling radiologists to make a more precise diagnosis." 

The ASPIRE Bellus II smart mammography workstation offers a multimodality view for radiologists in an exceptional hi-resolution display and also offers 2D and tomosynthesis comparisons. While supporting a range of DICOM formats, the system is designed around the unique requirements of mammography. The ASPIRE Bellus II incorporates key diagnostic features such as current and prior image comparison, quadrant view, tomosynthesis support and invert. To optimize workflow the ASPIRE Bellus II enables customization for reading protocols and personalized configuration. It received 510(k) clearance from the United States Food and Drug Administration in September 2017 and will begin shipping to customers in spring 2018.

At both conferences, Fujifilm will also exhibit the ASPIRE Cristalle digital mammography system with digital breast tomosynthesis (DBT) option. It combines state-of-the-art, Hexagonal Close Pattern (HCP) image capture technology and intelligent image processing, optimizing both contrast and dose based on auto recognition of breast characteristics. This advanced technology is designed to optimize image acquisition, regardless of breast composition and at a low dose. In addition, the ASPIRE Cristalle helps deliver noticeable patient comfort with its patented, flexible Comfort Paddle intended to provide gentle, even compression of the breast.

Visit Fujifilm at NCoBC at booth #809.

Visit Fujifilm at SBI booth #332.

SOURCE FUJIFILM Medical Systems U.S.A., Inc.